vTv Therapeutics Announces Results of Multiple Ascending Dose Study and Development Plan for HPP737, an Oral PDE4 Inhibitor for the Treatment of Psoriasis
HPP737 exhibited favorable safety and tolerability profile, with no dose limiting gastrointestinal side effects Results build on data from previous...